Lecture Date
June 7, 2024
Description
The Center for Cancer Research Grand Rounds provides a weekly series of lectures that discuss the most up-to-date research regarding new detection methods and treatment modalities and their potential applications. These lectures are designed to enhance professional effectiveness and lead to a change in patient care and management of disease by facilitating the movement of experimental concepts from the bench to the bedside.
Who Should Attend
This activity is intended for NCI scientists, clinicians and fellows.
CME Activity Code: 51105
Objectives
After attending this activity, the participant will demonstrate the ability to:
Describe Splicing factor mutations in MDS/AML and advances in xenograft models of MDS.
- Employ a multidisciplinary, cooperative, and iterative approach to the exchange of medical education across the breadth of Johns Hopkins Medicine and affiliate practitioners and educators.
- Improve the safety and quality of patient care by analyzing systems-based and practice-based processes.
- Translate recent research, new techniques, guidelines, etc. to clinical practice, based on the methodological quality of their design, validity, and applicability to patient care.
- Foster communication among healthcare stakeholders by exploring and integrating patient-centered, team-based strategies, when appropriate.
- Compare and contrast patient outcomes of past cases with current ones to inform treatment strategies.
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this regularly scheduled series- live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This series has been approved for a 52-week cycle beginning September 8, 2023.
Policy on Presenter and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the presenter and provider globally disclose conflicts of interest and any discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
Disclosure Summary
The following relationships have been reported for this activity:
No one else in a position to control content of this educational activity has disclosed a relevant financial relationship with any commercial interest.
Adam Sowalsky, Ph.D. - Member, Planning Committee
- Grant or Research Support: Astellas Pharma Inc.
Stephanie Halene, M.D - Speaker
- Grant or Research Support: STORM Therapeutics, AstraZeneca